LOS ANGELES – Shohei Ohtani sat out Thursday’s series finale against the Seattle Mariners with left knee soreness, and for the first time this season the Dodgers made the reason for his absence from the mound unmistakable.
“If it weren’t for the knee,” Andrew Friedman, the Dodgers’ president of baseball operations, said Thursday, “he would be pitching right now.”
That sentence reframed a month of careful language from Los Angeles, which had spent the weeks since the All-Star break describing Ohtani’s mound timeline in the vague terms that organizations prefer when they do not want to commit to a date. Ohtani last pitched July 3. He received a lubricant injection in the knee during the All-Star break after skipping the All-Star Game in Philadelphia to manage the injury. He threw a bullpen session on July 22 that did not produce the results the Dodgers needed. He has not pitched since.
Manager Dave Roberts described Thursday’s absence as precautionary and said Ohtani will return to the lineup Friday for the series opener against the Boston Red Sox. The knee remains the constraint. The mound is a different question.
Ohtani offered his own account Thursday: “My bicep’s not 100 percent. Just similar issue with the knee.”
The Dodgers won the Mariners finale 5-2 without him in the batting order. Los Angeles improved to 63-43 at the midpoint of July 31, sitting 5.5 games ahead in the NL West. Teoscar Hernandez filled the designated hitter spot; Kike Hernandez moved to left field to cover the absence. The division lead is not the immediate problem. The October question is.
Teams that build a roster around a two-way player accept a specific kind of risk: when the system works, it distorts what the competition can plan for. When it does not, the gap between what the roster was designed to do and what it can actually execute becomes visible. The Dodgers have enough depth to absorb Ohtani the hitter sitting out a game. They do not have a plan that survives October without him pitching.
Ohtani signed with Los Angeles in the winter of 2023 for ten years and $700 million, the largest contract in professional sports history at the time. The first year, he recovered from Tommy John surgery and did not pitch. The second year, he returned to the mound, won the NL Cy Young Award, and became the first player in baseball history to hit 50 home runs and steal 50 bases in the same season. The expectation heading into 2026 was that both sides of his game would function simultaneously for a full season. Four months in, the knee has not cooperated.
The biceps, which the Dodgers are now treating as secondary, was a concern earlier in the season. What Friedman’s comment Thursday clarified is that the fundamental constraint is structural: the knee is the gatekeeper for the mound, not the arm.
According to earlier reporting on Ohtani’s knee, the joint issue surfaced before the All-Star break, with the Dodgers adjusting his pitching schedule around it. The lubricant injection during the break was intended to reset the joint’s response. The July 22 bullpen session was the test. It did not pass.
Los Angeles acquired Tarik Skubal from Detroit before the MLB trade deadline, adding a proven ace to a rotation that cannot afford to wait indefinitely for Ohtani’s mound availability. Skubal gives the Dodgers an insurance policy for October. Ohtani, if healthy, gives them something no trade can replicate.
Yahoo Sports reported that Roberts cited the knee as the primary factor and said Ohtani will return to the batting lineup for Friday’s game, while the mound timeline remains unspecified.
Ohtani’s absence from the All-Star Game was the first public signal that knee management would define the second half of this season. The Mariners series finale on Thursday was the most recent confirmation.
The NL West lead, at 5.5 games, is not a concern for this month. The question the Dodgers will spend August managing is whether the knee can be maintained to a point where Ohtani pitches in October. Everything about the 2026 roster was constructed around that assumption. Right now, Thursday confirmed, only half of it is operational.
A roster built for $700 million to have both versions of Shohei Ohtani is currently operating with one. The other is available, pending resolution of a problem the front office has now described precisely once, clearly, and in terms that left no room for ambiguity. Friday begins a homestand against Boston. Ohtani’s name will appear in the lineup. The mound question will remain unanswered for at least another day, and possibly longer.
